In earlier clinical work, the alpibectir–ethionamide combination (AlpE) delivered a 7‑day early bactericidal activity signal comparable to isoniazid and has been generally well tolerated across Phase 1/2 settings. A separate 14‑day, open‑label Phase 2a assessing AlpE with first‑line TB drugs has completed enrollment with top‑line results due in Q2 2026.

The core development has now moved into a Phase 2b regimen-selection study within the EU’s UNITE4TB platform, where the first patient has been dosed in adults with drug‑susceptible pulmonary TB (NCT05807399). The design adds AlpE to rifampicin, pyrazinamide, and ethambutol for two months, followed by 18 weeks of rifampicin and isoniazid alone. Conducted across six African countries with LMU University Hospital Munich as sponsor, the trial targets dose finding, efficacy, safety, and pharmacokinetics and is slated to read out by year‑end 2027. In parallel, BioVersys plans a Phase 2 study in TB meningitis in the first half of 2026, signaling an intent to test the combination’s utility in severe extrapulmonary disease.

Strategically, the move advances a distinct “revival and potentiate” play: rather than stacking newer agents, BioVersys and GSK are attempting to restore and enhance the activity of ethionamide through alpibectir’s TRIC‑based mechanism. The two‑month intensive phase is effectively isoniazid‑sparing, which aligns with the growing operational and epidemiologic pressure from isoniazid resistance in settings otherwise classified as drug‑susceptible. It also fits the platform’s purpose: run head‑to‑head regimen experiments early, kill weak combinations quickly, and spare sponsors the cost and time of pushing suboptimal regimens into Phase 3. Public–private funding and an established site network de‑risk execution and enable biomarker and PK/PD integration that single‑asset programs struggle to finance.

For trial sites, the protocol introduces added complexity in a standard DS‑TB population: intensified safety monitoring for ethionamide‑related adverse events, rich PK sampling, and strict management of drug–drug interactions with rifampicin. UNITE4TB’s centralized operations and adaptive design should streamline data capture and interim decision‑making, but sites will still carry the burden of supply chain coordination for both investigational and legacy drugs and adherence oversight in high‑throughput settings. CROs and labs with TB capacity in Africa could see increased demand for culture conversion readouts, MIC testing, and modeling support. For sponsors and donors, the commercial calculus remains constrained: orphan designations in the US and EU help sustain development, but eventual uptake will hinge on pricing, fixed‑dose combination availability, and how the regimen competes against the WHO‑endorsed four‑month rifapentine–moxifloxacin option in DS‑TB and the expanding short‑course regimens in drug‑resistant disease.

Near term, two signals will matter: the Q2 2026 14‑day Phase 2a readout to confirm dose, safety, and early kill when layered onto first‑line therapy; and interim Phase 2b data on eight‑week culture conversion and tolerability under real‑world operational conditions. The key risks are well‑known: ethionamide’s GI and hepatic liabilities, potential rifamycin interactions, and the need to demonstrate either faster sterilization, non‑inferiority with superior tolerability, or clear utility in isoniazid‑resistant cases to justify regimen complexity and cost. Watch for movement on a true fixed‑dose combination and manufacturing scale‑up, any adaptive “go/no‑go” decisions within the UNITE4TB platform, and whether the meningeal TB study can establish a CNS penetration and safety profile robust enough to support a broader label. The broader question is whether potentiating an older agent can carve out a durable niche as DS‑TB standards shorten and donors push for streamlined, field‑ready regimens.

Source link: https://www.globenewswire.com/news-release/2026/03/12/3254275/0/en/BioVersys-Announces-First-Patient-Dosed-in-Phase-2b-Clinical-Trial-of-AlpE-in-Pulmonary-Tuberculosis.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.